bortezomib - Generic mfg.
zetomipzomib (KZR-616) - Kezar
α-Aminoboronic Acid Moieties in Boro Dipeptides Modulate Proteasome Subunit Selectivity and Provide Access to Compounds with Potent Anticancer and Anti-Inflammatory Activity. (PubMed, J Med Chem) - Dec 5, 2025 - "Although their cytotoxicity to cancer cells was not improved compared to bortezomib, selected compounds proved less toxic to noncancer cells and with anti-inflammatory activity comparable to that of zetomipzomib (KZR-616). The presented boro dipeptides with tailored P1 residues provide a basis for designing subunit-selective compounds with boronic acid as the warhead and optimized P2 and/or P3 positions." 
Journal • Immunology • Oncology
http://www.ncbi.nlm.nih.gov/pubmed/41344819
 
Andrej Šterman; Lara Smrdel; Martina Gobec; Nika Strašek Benedik; Stane Pajk; Stanislav Gobec
 
Dec 5, 2025
 
Prev Next